New molecularly targeted agents
Written by: Jonathan Simmons | Last reviewed: September 2013.
1. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011;23:245-51. 2. Yamanaka H, Seto Y, Tanaka E, et al. Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol 2013;23:1-7. 3. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 2012;6:245-50. 4. Kumar N, Goldminz AM, Kim N, Gottlieb AB. Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med 2013;11:96. 5. Clinicaltrials.gov. 6. AstraZeneca (AZN) will not proceed with fostamatinib; returns rights to Rigel (RIGL). StreetInsider.com; June 4, 2013. 7. Gomez-Puerta JA, Mocsa A. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Curr Top Med Chem 2013;13:760-73. 8. Fleischmann R, Poiley J, Stoilov R, et al. The oral S1P lyase inhibitor LX3305 (AKA LX2931) demonstrates favaorable safety and potential clinical benefit at 12-weeks in a Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy. Ann Rheum Dis 2011;70 (Suppl 3):87. 9. ChemoCentryx reports clinical efficacy of CCX354, a novel CCR1 inhibitor in a Phase II study in patients with rheumatoid arthritis. PR Newswire; November 8, 2011.